TOKYO, May 20 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) announced today that it has received a milestone payment from Velovia Pharma, LLC related to the exercise of an option license for one of four development compounds previously transferred to Velovia Pharma.
The agreement was signed on April 03, 2024, granting Velovia Pharma exclusive rights to evaluate, develop, manufacture, and sell animal pharmaceutical products containing the licensed compounds. Under the terms of the contract, RaQualia Pharma will now be eligible to receive further milestone payments based on the progress of the compound's development. Additionally, should the product reach commercial sales, RaQualia Pharma could also earn royalties and additional sales-based milestones from Velovia Pharma.
This milestone payment will be recognized as revenue in the second quarter of the fiscal year ending December 2026. The impact of this transaction on the consolidated earnings forecast for the fiscal year ending December 2026 has already been incorporated into the projections released on February 13, 2026. Going forward, RaQualia Pharma plans to strengthen its collaboration with Velovia Pharma and continue providing development support aimed at maximizing the value of the animal pharmaceutical product.
🟢 Confidence: High AI-translated content.